Keybank National Association OH Buys 25,993 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on Apr 23rd, 2023

Keybank National Association OH grew its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,666,719 shares of the company’s stock after buying an additional 25,993 shares during the period. Johnson & Johnson accounts for approximately 1.4% of Keybank National Association OH’s portfolio, making the stock its 11th largest holding. Keybank National Association OH owned approximately 0.06% of Johnson & Johnson worth $294,426,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lincoln Capital Corp grew its holdings in shares of Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after purchasing an additional 183 shares in the last quarter. Ieq Capital LLC grew its holdings in shares of Johnson & Johnson by 5.1% during the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after purchasing an additional 6,154 shares in the last quarter. RFG Advisory LLC boosted its stake in Johnson & Johnson by 2.7% in the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after buying an additional 594 shares in the last quarter. Willis Investment Counsel boosted its stake in Johnson & Johnson by 0.4% in the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after buying an additional 1,358 shares in the last quarter. Finally, FDx Advisors Inc. boosted its stake in Johnson & Johnson by 0.3% in the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock worth $8,237,000 after buying an additional 153 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors.

Johnson & Johnson Price Performance

Shares of Johnson & Johnson stock opened at $162.69 on Friday. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The company has a market cap of $423.69 billion, a PE ratio of 34.04, a P/E/G ratio of 2.63 and a beta of 0.53. The business has a 50 day moving average of $157.49 and a 200 day moving average of $166.96. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 35.53% and a net margin of 13.22%. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.67 earnings per share. As a group, equities research analysts forecast that Johnson & Johnson will post 10.65 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.93%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.

Analyst Ratings Changes

JNJ has been the subject of several research reports. Atlantic Securities cut their target price on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, February 1st. SVB Leerink cut their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. StockNews.com initiated coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating for the company. Finally, Morgan Stanley increased their price objective on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $173.00.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.20% of the company’s stock.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.